guest ::
| Home > Publications database > Semi-solid MT and APTw CEST-MRI predict clinical outcome of patients with glioma early after radiotherapy. > print |
| Home > Publications database > Semi-solid MT and APTw CEST-MRI predict clinical outcome of patients with glioma early after radiotherapy. > print |
| 001 | 276866 | ||
| 005 | 20240229155005.0 | ||
| 024 | 7 | _ | |a 10.1002/mrm.29746 |2 doi |
| 024 | 7 | _ | |a pmid:37317562 |2 pmid |
| 024 | 7 | _ | |a 1522-2594 |2 ISSN |
| 024 | 7 | _ | |a 0740-3194 |2 ISSN |
| 024 | 7 | _ | |a altmetric:150088367 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-01178 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kroh, Florian |0 P:(DE-He78)a803bc5fee5b7b2093f0fe6074f3d2ea |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Semi-solid MT and APTw CEST-MRI predict clinical outcome of patients with glioma early after radiotherapy. |
| 260 | _ | _ | |a New York, NY [u.a.] |c 2023 |b Wiley-Liss |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1690812358_20266 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:E010#EA:E020#LA:E010# / 2023 Oct;90(4):1569-1581 |
| 520 | _ | _ | |a The purpose of this study was to compare the potential of asymmetry-based (APTwasym ), Lorentzian-fit-based (PeakAreaAPT and MTconst ), and relaxation-compensated (MTRRex APT and MTRRex MT) CEST contrasts of the amide proton transfer (APT) and semi-solid magnetization transfer (ssMT) for early response assessment and prediction of progression-free survival (PFS) in patients with glioma.Seventy-two study participants underwent CEST-MRI at 3T from July 2018 to December 2021 in a prospective clinical trial four to 6 wk after the completion of radiotherapy for diffuse glioma. Tumor segmentations were performed on T2w -FLAIR and contrast-enhanced T1w images. Therapy response assessment and determination of PFS were performed according to response assessment in neuro oncology (RANO) criteria using clinical follow-up data with a median observation time of 9.2 mo (range, 1.6-40.8) and compared to CEST MRI metrics. Statistical testing included receiver operating characteristic analyses, Mann-Whitney-U-test, Kaplan-Meier analyses, and logrank-test.MTconst (AUC = 0.79, p < 0.01) showed a stronger association with RANO response assessment compared to PeakAreaAPT (AUC = 0.71, p = 0.02) and MTRRex MT (AUC = 0.71, p = 0.02), and enabled differentiation of participants with pseudoprogression (n = 8) from those with true progression (AUC = 0.79, p = 0.02). Furthermore, MTconst (HR = 3.04, p = 0.01), PeakAreaAPT (HR = 0.39, p = 0.03), and APTwasym (HR = 2.63, p = 0.02) were associated with PFS. MTRRex APT was not associated with any outcome.MTconst , PeakAreaAPT, and APTwasym imaging predict clinical outcome by means of progression-free survival. Furthermore, MTconst enables differentiation of radiation-induced pseudoprogression from disease progression. Therefore, the assessed metrics may have synergistic potential for supporting clinical decision making during follow-up of patients with glioma. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a amide proton transfer imaging |2 Other |
| 650 | _ | 7 | |a chemical exchange saturation transfer |2 Other |
| 650 | _ | 7 | |a glioma |2 Other |
| 650 | _ | 7 | |a magnetic resonance imaging |2 Other |
| 650 | _ | 7 | |a radiotherapy |2 Other |
| 650 | _ | 7 | |a semisolid magnetization transfer imaging |2 Other |
| 700 | 1 | _ | |a von Knebel Doeberitz, Nikolaus |0 P:(DE-He78)857bbcdb8f5f582e00795df8b957767d |b 1 |e First author |u dkfz |
| 700 | 1 | _ | |a Breitling, Johannes |0 P:(DE-He78)8a54e49721e8ba58de289702bad026d9 |b 2 |
| 700 | 1 | _ | |a Maksimovic, Srdjan |0 P:(DE-He78)2125f6b64a5de735c85e8f646edef7a9 |b 3 |
| 700 | 1 | _ | |a König, Laila |b 4 |
| 700 | 1 | _ | |a Adeberg, Sebastian |b 5 |
| 700 | 1 | _ | |a Scherer, Moritz |b 6 |
| 700 | 1 | _ | |a Unterberg, Andreas |b 7 |
| 700 | 1 | _ | |a Bendszus, Martin |b 8 |
| 700 | 1 | _ | |a Wick, Wolfgang |b 9 |
| 700 | 1 | _ | |a Bachert, Peter |0 P:(DE-He78)29b2f01310f7022916255ddba2750f9b |b 10 |u dkfz |
| 700 | 1 | _ | |a Debus, Jürgen |0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |b 11 |u dkfz |
| 700 | 1 | _ | |a Ladd, Mark E |0 P:(DE-He78)022611a2317e4de40fd912e0a72293a8 |b 12 |u dkfz |
| 700 | 1 | _ | |a Schlemmer, Heinz-Peter |0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec |b 13 |u dkfz |
| 700 | 1 | _ | |a Korzowski, Andreas |0 P:(DE-He78)577a5c61f44b8023e229610afbc7cd4e |b 14 |u dkfz |
| 700 | 1 | _ | |a Goerke, Steffen |0 P:(DE-HGF)0 |b 15 |
| 700 | 1 | _ | |a Paech, Daniel |0 P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc |b 16 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1002/mrm.29746 |g p. mrm.29746 |0 PERI:(DE-600)1493786-4 |n 4 |p 1569-1581 |t Magnetic resonance in medicine |v 90 |y 2023 |x 1522-2594 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:276866 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)a803bc5fee5b7b2093f0fe6074f3d2ea |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)857bbcdb8f5f582e00795df8b957767d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)8a54e49721e8ba58de289702bad026d9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)2125f6b64a5de735c85e8f646edef7a9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)29b2f01310f7022916255ddba2750f9b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)022611a2317e4de40fd912e0a72293a8 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)577a5c61f44b8023e229610afbc7cd4e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2022-11-08 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2022-11-08 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-08 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MAGN RESON MED : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-21 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-10-21 |
| 920 | 2 | _ | |0 I:(DE-He78)E010-20160331 |k E010 |l E010 Radiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E020-20160331 |k E020 |l E020 Med. Physik in der Radiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E010-20160331 |k E010 |l E010 Radiologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)E050-20160331 |k E050 |l E050 KKE Strahlentherapie |x 2 |
| 920 | 0 | _ | |0 I:(DE-He78)E020-20160331 |k E020 |l E020 Med. Physik in der Radiologie |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)E010-20160331 |k E010 |l E010 Radiologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E020-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E010-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E050-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|